ArticleCanadian journal of public health = Revue canadienne de sante publique2026
Earlier screening, better outcomes? Revisiting breast cancer screening guidelines for women in their 40s.
Article in Canadian journal of public health = Revue canadienne de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
While mammography screening programmes improve early detection and reduce mortality for individuals aged 50-74, its extension to those aged 40-49 remains debated. In Canada, breast screening eligibility varies between provinces/territories, with Ontario lowering its eligibility age from 50 to 40 in 2024. This commentary examines recent evidence, including observational studies and simulation models, suggesting that mammography screening from age 40 may offer net benefits. Additionally, using data from Ontario Health (Cancer Care Ontario), we compared stage at diagnosis and 5-year survival rates among 18,639 women aged 40-51 diagnosed with breast cancer (2009-2017). Individuals aged 40-49 had comparable stage at diagnosis and 5-year survival rates to unscreened individuals aged 50-51. Meanwhile, screened individuals aged 50-51 demonstrated the earliest stage at diagnosis and highest 5-year survival rate. Our analysis illustrates the arbitrary nature of an age-based screening threshold at 50. We demonstrate that outcomes for women aged 40-49 resemble those of unscreened women aged 50-51, who were just above the eligibility cutoff. While expanding screening may increase upfront costs, these could be offset by avoiding late-stage treatments and integrating risk-stratified approaches. Overall, women in their 40s may benefit from organized screening programs through earlier detection and improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.